<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK154652" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK154652/" /><meta name="ncbi_pagename" content="Congenital Erythropoietic Porphyria - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Congenital Erythropoietic Porphyria - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Congenital Erythropoietic Porphyria" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/04/07" /><meta name="citation_author" content="Angelika Erwin" /><meta name="citation_author" content="Manisha Balwani" /><meta name="citation_author" content="Robert J Desnick" /><meta name="citation_author" content="Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network" /><meta name="citation_pmid" content="24027798" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK154652/" /><meta name="citation_keywords" content="Günther Disease" /><meta name="citation_keywords" content="Günther disease" /><meta name="citation_keywords" content="Erythroid transcription factor" /><meta name="citation_keywords" content="Uroporphyrinogen-III synthase" /><meta name="citation_keywords" content="GATA1" /><meta name="citation_keywords" content="UROS" /><meta name="citation_keywords" content="Congenital Erythropoietic Porphyria" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Congenital Erythropoietic Porphyria" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Angelika Erwin" /><meta name="DC.Contributor" content="Manisha Balwani" /><meta name="DC.Contributor" content="Robert J Desnick" /><meta name="DC.Contributor" content="Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network" /><meta name="DC.Date" content="2016/04/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK154652/" /><meta name="description" content="Congenital erythropoietic porphyria (CEP) is characterized in most individuals by severe cutaneous photosensitivity with blistering and increased friability of the skin over light-exposed areas. Onset in most affected individuals occurs at birth or early infancy. The first manifestation is often pink to dark red discoloration of the urine. Hemolytic anemia is common and can range from mild to severe, with some affected individuals requiring chronic blood transfusions. Porphyrin deposition may lead to corneal ulcers and scarring, reddish-brown discoloration of the teeth (erythrodontia), and mild bone loss and/or expansion of the bone marrow. The phenotypic spectrum, however, is broad and ranges from non-immune hydrops fetalis in utero to late-onset disease with only mild cutaneous manifestations in adulthood." /><meta name="og:title" content="Congenital Erythropoietic Porphyria" /><meta name="og:type" content="book" /><meta name="og:description" content="Congenital erythropoietic porphyria (CEP) is characterized in most individuals by severe cutaneous photosensitivity with blistering and increased friability of the skin over light-exposed areas. Onset in most affected individuals occurs at birth or early infancy. The first manifestation is often pink to dark red discoloration of the urine. Hemolytic anemia is common and can range from mild to severe, with some affected individuals requiring chronic blood transfusions. Porphyrin deposition may lead to corneal ulcers and scarring, reddish-brown discoloration of the teeth (erythrodontia), and mild bone loss and/or expansion of the bone marrow. The phenotypic spectrum, however, is broad and ranges from non-immune hydrops fetalis in utero to late-onset disease with only mild cutaneous manifestations in adulthood." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK154652/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/cep/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK154652/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C8AFEDFC888410000000003AE01C1.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK154652_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK154652_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cda1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cftd/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK154652_"><span class="title" itemprop="name">Congenital Erythropoietic Porphyria</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: G&#x000fc;nther Disease</div><p class="contrib-group"><span itemprop="author">Angelika Erwin</span>, MD, PhD, <span itemprop="author">Manisha Balwani</span>, MD, MS, <span itemprop="author">Robert J Desnick</span>, MD, PhD, FACMG; <span itemprop="author">Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network</span>.</p><a data-jig="ncbitoggler" href="#__NBK154652_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK154652_ai__"><div class="contrib half_rhythm"><span itemprop="author">Angelika Erwin</span>, MD, PhD<div class="affiliation small">Cleveland Clinic<br />Cleveland, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.fcc@aniwre" class="oemail">gro.fcc@aniwre</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Manisha Balwani</span>, MD, MS<div class="affiliation small">Icahn School of Medicine at Mount Sinai<br />New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@inawlab.ahsinam" class="oemail">ude.mssm@inawlab.ahsinam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Robert J Desnick</span>, MD, PhD, FACMG<div class="affiliation small">Icahn School of Medicine at Mount Sinai<br />New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mssm@kcinsed.trebor" class="oemail">ude.mssm@kcinsed.trebor</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network</span><sup><a href="#cep.Tb.an4" class="bk_pop">*</a></sup></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 12, 2013</span>; Last Update: <span itemprop="dateModified">April 7, 2016</span>.</p><p><em>Estimated reading time: 24 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="cep.Summary" itemprop="description"><h2 id="_cep_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Congenital erythropoietic porphyria (CEP) is characterized in most individuals by severe cutaneous photosensitivity with blistering and increased friability of the skin over light-exposed areas. Onset in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals occurs at birth or early infancy. The first manifestation is often pink to dark red discoloration of the urine. Hemolytic anemia is common and can range from mild to severe, with some affected individuals requiring chronic blood transfusions. Porphyrin deposition may lead to corneal ulcers and scarring, reddish-brown discoloration of the teeth (erythrodontia), and mild bone loss and/or expansion of the bone marrow. The phenotypic spectrum, however, is broad and ranges from non-immune hydrops fetalis in utero to late-onset disease with only mild cutaneous manifestations in adulthood<i>.</i></p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of CEP is supported by the biochemical findings of markedly decreased uroporphyrinogen (URO)-synthase activity in erythrocytes and/or markedly increased levels of urinary uroporphyrin I and coproporphyrin I isomers. The diagnosis is confirmed most commonly by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>UROS</i> pathogenic variants or on rare occasion by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>GATA1</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> There is no FDA-approved treatment for CEP or specific treatment for the photosensitivity. The only effective management is prevention of blistering by avoidance of sun and light exposure, including the long-wave ultraviolet light that passes through window glass or is emitted from artificial light sources. Therefore, the use of protective clothing, wraparound sunglasses, protective window films, reddish incandescent bulbs, filtering screens for fluorescent lights, and opaque sunscreens containing zinc oxide or titanium oxide is recommended. Wound care is necessary to prevent infection of opened blisters; surgical intervention may be necessary; blood transfusions are necessary when hemolysis is significant. Bone marrow transplantation (BMT) is the only cure for CEP and should be considered in children with severe cutaneous and hematologic involvement.</p><p><i>Prevention of primary manifestations:</i> Strict avoidance of sunlight and other long-wave UV light exposure.</p><p><i>Prevention of secondary complications:</i> Vitamin D supplementation, immunization for hepatitis A and B.</p><p><i>Surveillance:</i> Monitor hematologic indices to assess hemolysis every six months. In those receiving transfusions: monitor for hemolysis more frequently and for iron overload. Monitor hepatic function and vitamin D 25-OH every six to twelve months in all patients.</p><p><i>Agents/circumstances to avoid:</i> Avoidance of sunlight and UV light (see <i>Treatment of manifestations</i>). In those with hepatic dysfunction: avoid drugs that may induce cholestasis.</p><p><i>Evaluation of relatives at risk:</i> Presymptomatic diagnosis is warranted in relatives at risk for initiation of early intervention (no phototherapy, strict sun protection) and future monitoring for signs of hemolytic anemia.</p><p><i>Pregnancy management:</i> Protective filters for artificial lights should be used in the delivery/operating room to prevent phototoxic damage to the mother during delivery.</p><p><i>Other:</i> Neither beta-carotene nor phototherapy with narrow-band ultraviolet B radiation has been beneficial.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>CEP caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>UROS</i> pathogenic variants is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> (AR) manner. CEP caused by a <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> (XL) manner.</p><ul><li class="half_rhythm"><div><b>AR CEP.</b> At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are asymptomatic. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</div></li><li class="half_rhythm"><div><b>XL CEP.</b> If the mother of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygotes and can be either asymptomatic or have a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li></ul></div></div><div id="cep.Diagnosis"><h2 id="_cep_Diagnosis_">Diagnosis</h2><p>Formal diagnostic criteria have not been established for <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria (CEP).</p><div id="cep.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Congenital erythropoietic porphyria (CEP) <b>should be suspected</b> in individuals with the following clinical and laboratory findings.</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Non-immune hydrops fetalis</div></li><li class="half_rhythm"><div>Signs of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria</div><ul><li class="half_rhythm"><div>Pink to dark red discoloration of the urine (pink or dark red urine-stained diapers are often the first sign in infants)</div></li><li class="half_rhythm"><div>Hemolytic anemia</div></li><li class="half_rhythm"><div>Severe cutaneous photosensitivity with onset usually in infancy or early childhood</div></li><li class="half_rhythm"><div>Blisters and vesicles in light-exposed areas, which are prone to rupture and infection</div></li><li class="half_rhythm"><div>Scarring and deformities (photomutilation) of digits and facial features, caused by recurrent blistering, infections, and bone resorption</div></li><li class="half_rhythm"><div>In light-exposed areas: friable skin, skin thickening, hypo- and hyperpigmentation</div></li><li class="half_rhythm"><div>Reddish-brown discoloration of teeth (fluoresce on exposure to long-wave ultraviolet light), also called erythrodontia</div></li><li class="half_rhythm"><div>Corneal ulcers and scarring</div></li><li class="half_rhythm"><div>Hypertrichosis of face and extremities</div></li></ul></li></ul><p><b>Laboratory findings.</b> Markedly increased levels of uroporphyrin I and coproporphyrin I isomers in erythrocytes, urine, or amniotic fluid as well as coproporphyrin I in stool (see <a class="figpopup" href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" rid-figpopup="figcepTbiochemicalcharacteristicsofcon" rid-ob="figobcepTbiochemicalcharacteristicsofcon">Table 1</a>)</p><div id="cep.T.biochemical_characteristics_of_con" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Biochemical Characteristics of Congenital Erythropoietic Porphyria (CEP)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.biochemical_characteristics_of_con_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Defect</th><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enzyme Activity&#x000a0;<sup>1</sup></th><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Uroporphyrin&#x000a0;<sup>1</sup></th><th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coproporphyrin&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Uroporphyrinogen III synthase (URO-synthase)&#x000a0;<sup>2</sup></td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_2" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">Undetectable to ~10% of normal mean activity in erythrocytes</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Erythrocytes</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td></tr><tr><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Urine</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td></tr><tr><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Stool</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td></tr><tr><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Amniotic&#x000a0;fluid&#x000a0;<sup>3</sup></td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td><td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">&#x02191; = markedly elevated</p></div></dd><dt>1. </dt><dd><div id="cep.TF.1.1"><p class="no_margin">The deficient activity of uroporphyrinogen III synthase EC 4.2.1.75, encoded by UROS, results in non-enzymatic conversion of hydroxymethylbilane to uroporphyrinogen I, which is then metabolized to coproporphyrinogen I. Coproporphyrinogen I cannot be metabolized further. These metabolites are then oxidized to uroporphyrin I and coproporphyrin I, respectively, which are non-physiologic and pathogenic.</p></div></dd><dt>2. </dt><dd><div id="cep.TF.1.2"><p class="no_margin">The assay for the enzyme uroporphyrinogen III synthase is available on a clinical basis and can be used to establish the diagnosis of CEP.</p></div></dd><dt>3. </dt><dd><div id="cep.TF.1.3"><p class="no_margin">Amniotic fluid appears red to dark brown. Prenatal diagnosis is also possible by demonstrating markedly deficient URO-synthase activity in cultured amniotic cells or chorionic villi cells [<a class="bk_pop" href="#cep.REF.da_khadahmane.2001.180">Da&#x000ef;kha-Dahmane et al 2001</a>].</p></div></dd></dl></div></div></div></div><div id="cep.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of CEP <b>is established</b> by biochemical testing and should be confirmed by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>UROS</i> or, on rare occasion, by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>GATA1</i> [<a class="bk_pop" href="#cep.REF.phillips.2007.2618">Phillips et al 2007</a>] (<a class="figpopup" href="/books/NBK154652/table/cep.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figcepTmoleculargenetictestingusedin" rid-ob="figobcepTmoleculargenetictestingusedin">Table 2</a>). If the diagnosis cannot be established by the results of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, analysis of URO-synthase activity in erythrocytes can be pursued (<a class="figpopup" href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" rid-figpopup="figcepTbiochemicalcharacteristicsofcon" rid-ob="figobcepTbiochemicalcharacteristicsofcon">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></div><ul><li class="half_rhythm"><div>Typically <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>UROS</i> is performed first, followed by <i>UROS</i> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div>If no <i>UROS</i> pathogenic variants are detected, sequencing of <i>GATA1</i> should be considered.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>UROS</i> and <i>GATA1</i> and other genes of interest (see <a href="#cep.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>UROS</i> and <i>GATA1</i>) fails to confirm a diagnosis in an individual with features of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="cep.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Congenital Erythropoietic Porphyria (CEP)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of CEP Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method</th></tr><tr><th headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UROS</i></td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~98%&#x000a0;<sup>5</sup></td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~90%&#x000a0;<sup>6,&#x000a0;7</sup></td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~10%&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GATA1</i></td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~1%&#x000a0;<sup>9</sup></td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 10</td><td headers="hd_h_cep.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_cep.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="cep.TF.2.1"><p class="no_margin">See <a href="/books/NBK154652/#cep.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="cep.TF.2.2"><p class="no_margin">See <a href="#cep.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="cep.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="cep.TF.2.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="cep.TF.2.5"><p class="no_margin"><a class="bk_pop" href="#cep.REF.stenson.2003.577">Stenson et al [2003]</a></p></div></dd><dt>6. </dt><dd><div id="cep.TF.2.6"><p class="no_margin">Missense/<a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, small deletions and small duplications, and an <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, all detectable by routine sequencing, have been reported (see <a href="#cep.Molecular_Genetics">Molecular Genetics</a>).</p></div></dd><dt>7. </dt><dd><div id="cep.TF.2.7"><p class="no_margin">Six regulatory variants approximately 200 base pairs upstream of the ATG can be detected by sequencing if the DNA region is included in the analysis.</p></div></dd><dt>8. </dt><dd><div id="cep.TF.2.8"><p class="no_margin">Two gross deletions, two gross duplications, and one complex rearrangement have been reported [<a class="bk_pop" href="#cep.REF.boulechfar.1992.320">Boulechfar et al 1992</a>, <a class="bk_pop" href="#cep.REF.shady.2002.980">Shady et al 2002</a>, <a class="bk_pop" href="#cep.REF.katugampola.2012a.888">Katugampola et al 2012a</a>]</p></div></dd><dt>9. </dt><dd><div id="cep.TF.2.9"><p class="no_margin">A <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (p.Arg216Trp) was identified in three unrelated individuals with CEP and hematological abnormalities [<a class="bk_pop" href="#cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bk_pop" href="#cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</p></div></dd><dt>10. </dt><dd><div id="cep.TF.2.10"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd></dl></div></div></div></div></div><div id="cep.Clinical_Characteristics"><h2 id="_cep_Clinical_Characteristics_">Clinical Characteristics</h2><div id="cep.Clinical_Description"><h3>Clinical Description</h3><p>In most individuals with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria (CEP) severe cutaneous photosensitivity begins in early infancy; the first manifestation is often pink to dark red discoloration of the urine. Hemolytic anemia is common and can be mild to severe, requiring chronic blood transfusions in some. The phenotypic spectrum ranges from severe (non-immune hydrops fetalis) to milder disease (adult-onset with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> cutaneous manifestations [<a class="bk_pop" href="#cep.REF.warner.1992.693">Warner et al 1992</a>]). (See <a href="#cep.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a> for predictors of disease severity.)</p><p><b>Skin.</b> Cutaneous photosensitivity is present at birth or early infancy and is characterized by blistering and increased friability of the skin over light-exposed areas. Bullae and vesicles are filled with serous fluid and are prone to rupture. Secondary infections with scarring and bone resorption (photomutilation) may lead to deformity and disfigurement of fingers, toes, and facial features including the nose, ears, and eyelids. Skin thickening, focal hyper- or hypopigmentation, and hypertrichosis of face and extremities may occur [<a class="bk_pop" href="#cep.REF.pohfitzpatrick.1986.291">Poh-Fitzpatrick 1986</a>].</p><p>Photosensitivity symptoms are provoked mainly by visible light (400-410 nm Soret wavelength) and to a lesser degree by wavelengths in the long-wave UV region. Affected individuals are also sensitive to sunlight that passes through window glass that does not filter long-wave UVA or visible light as well as to light from artificial light sources.</p><p>Unlike the cutaneous manifestations in <a href="/books/n/gene/epp-ar/">erythropoietic protoporphyria</a> (EPP), symptoms such as tingling, burning, itching, or swelling usually do not occur in persons with CEP after light exposure.</p><p><b>Hematologic involvement.</b> Mild to severe hemolytic anemia with anisocytosis, poikilocytosis, polychromasia, basophilic stippling, and reticulocytosis is common in CEP. Findings also include: the absence of haptoglobin, increased unconjugated bilirubin, and increased fecal urobilinogen [<a class="bk_pop" href="#cep.REF.schmid.1955.416">Schmid et al 1955</a>]. Hemolysis presumably results from the accumulation of uroporphyrinogen I in the erythrocytes (see <a href="#cep.Pathophysiology">Pathophysiology</a>) [<a class="bk_pop" href="#cep.REF.bishop.2006.645">Bishop et al 2006</a>].</p><p>Those with severe hemolytic anemia often require chronic erythrocyte transfusions, which decreases porphyrin production by suppressing erythropoiesis, but can lead to iron overload and other complications [<a class="bk_pop" href="#cep.REF.piomelli.1986.1029">Piomelli et al 1986</a>].</p><p>Secondary splenomegaly may develop as a consequence of hemolytic anemia. In addition to worsening the anemia, it can also result in leukopenia and thrombocytopenia, which may be associated with significant bleeding [<a class="bk_pop" href="#cep.REF.pain.1975.621">Pain et al 1975</a>, <a class="bk_pop" href="#cep.REF.weston.1978.921">Weston et al 1978</a>, <a class="bk_pop" href="#cep.REF.phillips.2007.2618">Phillips et al 2007</a>].</p><p><b>Ophthalmologic involvement.</b> Deposition of porphyrins may lead to corneal ulcers and scarring, which can ultimately lead to blindness. Other ocular manifestations can include scleral necrosis, necrotizing scleritis, seborrheic blepharitis, keratoconjunctivitis, sclerokeratitis, and ectropion [<a class="bk_pop" href="#cep.REF.oguz.1993.671">Oguz et al 1993</a>, <a class="bk_pop" href="#cep.REF.venkatesh.2000.314">Venkatesh et al 2000</a>, <a class="bk_pop" href="#cep.REF.siddique.2011.97">Siddique et al 2011</a>].</p><p><b>Erythrodontia.</b> Porphyrin deposition in the teeth produces a reddish-brown color, termed erythrodontia. The teeth may fluoresce on exposure to long-wave ultraviolet light.</p><p><b>Bone involvement.</b> Deposition of porphyrins in bone causes mild bone loss (osteopenia on x-ray) due to demineralization [<a class="bk_pop" href="#cep.REF.piomelli.1986.1029">Piomelli et al 1986</a>, <a class="bk_pop" href="#cep.REF.laorr.1994.307">Laorr &#x00026; Greenspan 1994</a>, <a class="bk_pop" href="#cep.REF.fritsch.1997.594">Fritsch et al 1997</a>, <a class="bk_pop" href="#cep.REF.kontos.2003.160">Kontos et al 2003</a>]. It can also cause expansion of the bone marrow, which can lead to hyperplastic bone marrow observed on biopsy [<a class="bk_pop" href="#cep.REF.pohfitzpatrick.1986.291">Poh-Fitzpatrick 1986</a>, <a class="bk_pop" href="#cep.REF.anderson.2001">Anderson et al 2001</a>].</p><p><b>Vitamin D deficiency.</b> Individuals with CEP who avoid sunlight are at risk for vitamin D deficiency.</p></div><div id="cep.Pathophysiology"><h3>Pathophysiology</h3><p>CEP results from markedly decreased (but not absent) URO-synthase activity (&#x0003c;1 to ~10% of normal). When expressed in vitro, the residual enzyme activity of individual pathogenic variants ranges from less than 1.0% to approximately 35% [<a class="bk_pop" href="#cep.REF.desnick.2002.779">Desnick &#x00026; Astrin 2002</a>].</p><p>URO-synthase, the fourth enzyme in the heme biosynthesis pathway, normally converts hydroxymethylbilane (HMB) to uroporphyrinogen III. When URO-synthase activity is deficient, HMB accumulates primarily in the erythron and is non-enzymatically converted to uroporphyrinogen I. Decarboxylation of uroporphyrinogen I by URO-decarboxylase leads to formation of hepta-, hexa-, and pentacarboxyl porphyrinogen I isomers, with coproporphyrinogen I being the final product. Since coproporphyrinogen oxidase is specific for the III isomer, coproporphyrinogen I cannot be further metabolized to heme and is therefore non-physiologic. Isomer I porphyrinogens are pathogenic when they accumulate in large amounts and are auto-oxidized to their corresponding porphyrins [<a class="bk_pop" href="#cep.REF.piomelli.1986.1029">Piomelli et al 1986</a>, <a class="bk_pop" href="#cep.REF.pohfitzpatrick.1988">Poh-Fitzpatrick et al 1988</a>].</p><p>Porphyrinogen I isomers accumulate in bone marrow erythroid precursors; erythrocytes undergo auto-oxidation, which causes damage of the erythrocytes and hemolysis. Porphyrin I isomers are released into the circulation and deposited in skin, bone, and other tissues as well as excreted in urine and feces [<a class="bk_pop" href="#cep.REF.desnick.1998.77">Desnick et al 1998</a>].</p><p>Urinary porphyrin excretion is markedly increased (100-1,000 times normal) and consists mainly of uroporphyrin I and coproporphyrin I, with lesser increases in hepta-, hexa-, and pentacarboxyl porphyrin isomers [<a class="bk_pop" href="#cep.REF.fritsch.1997.594">Fritsch et al 1997</a>]. While isomer I porphyrins are predominant, isomer III porphyrins are also increased.</p><p>Cutaneous photosensitivity with blistering and increased friability occurs because the porphyrins deposited in the skin are photocatalytic and cytotoxic compounds [<a class="bk_pop" href="#cep.REF.pohfitzpatrick.1985">Poh-Fitzpatrick 1985</a>]. Presumably, exposure of the skin to sunlight or other sources of long-wave ultraviolet light in the Soret band (400-410 nm) leads to a phototoxic excitation of the accumulated uroporphyrin I and coproporphyrin I isomers. This results in formation of singlet oxygen and other oxygen radicals, which presumably produce tissue and vessel damage [<a class="bk_pop" href="#cep.REF.kaufman.1967.210">Kaufman et al 1967</a>, <a class="bk_pop" href="#cep.REF.bickers.1987.261">Bickers 1987</a>, <a class="bk_pop" href="#cep.REF.dawe.2002.680">Dawe et al 2002</a>].</p><p>The bone marrow contains much larger amounts of porphyrins (mostly uroporphyrin I and coproporphyrin I) than other tissues and hemolysis is almost always present in persons with CEP. Whether it is accompanied by anemia depends on whether erythroid hyperplasia is sufficient to compensate for the increased rate of erythrocyte destruction, which may vary over time. More severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are transfusion dependent.</p><p>Splenomegaly usually develops secondary to hemolysis and can also lead to thrombocytopenia and leukopenia. In addition, porphyrin deposition also occurs in the spleen and to a lesser degree in the liver.</p></div><div id="cep.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> that have been established in CEP are largely determined by the amount of residual enzyme activity encoded by the specific mutated alleles.</p><p>The most common <i>UROS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.217T&#x0003e;C (p.Cys73Arg)</a>, is observed in about one third of individuals with CEP.</p><ul><li class="half_rhythm"><div>Homozygosity for the c.217T&#x0003e;C (p.Cys73Arg) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> results in less than 1% of normal URO-synthase activity and a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that may manifest as non-immune hydrops fetalis [<a class="bk_pop" href="#cep.REF.frank.1998.225">Frank et al 1998</a>, <a class="bk_pop" href="#cep.REF.desnick.2002.779">Desnick &#x00026; Astrin 2002</a>].</div></li><li class="half_rhythm"><div>Compound heterozygosity for the c.217T&#x0003e;C (p.Cys73Arg) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that expresses a very low level of residual activity results in a severe or moderately severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li></ul><p>In contrast, individuals with pathogenic variants expressing higher residual activities such as <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.244G&#x0003e;T (p.Val82Phe)</a> (35% of normal activity in vitro), <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.311C&#x0003e;T (p.Ala104Val)</a> (7.7% of normal activity in vitro), and <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.197C&#x0003e;T (p.Ala66Val)</a> (14.5% of normal activity in vitro) have milder phenotypes even if heteroallelic for c.217T&#x0003e;C (p.Cys73Arg) or another <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> with very low or almost absent residual enzyme activity.</p><p>Determination of <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> for erythroid-specific promoter pathogenic variants (see <a href="#cep.Molecular_Genetics">Molecular Genetics</a>) showed the following:</p><ul><li class="half_rhythm"><div>Compound heterozygotes with the <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.-203T&#x0003e;C</a> (reported as -70T&#x0003e;C) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (2.9% of normal activity in vitro) in combination with the <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.217T&#x0003e;C</a>
<a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">(p.Cys73Arg)</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> led to non-immune hydrops fetalis [<a class="bk_pop" href="#cep.REF.solis.2001.753">Solis et al 2001</a>].</div></li><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.-223C&#x0003e;A</a> (-90C&#x0003e;A) <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (8.3% of normal activity in vitro) when in compound heterozygosity with another allele with low residual enzyme activity <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">(c.673G&#x0003e;A (p.Gly225Ser)</a>, 1.2% of normal activity in vitro) led to a moderately severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in one individual [<a class="bk_pop" href="#cep.REF.solis.2001.753">Solis et al 2001</a>].</div></li><li class="half_rhythm"><div>The two other known erythrocyte-specific promoter pathogenic variants, <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.-209G&#x0003e;A</a> (-76G&#x0003e;A) and <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.-219C&#x0003e;A</a> (-86C&#x0003e;A), with high residual activities (53.9% and 43.4% of normal in vitro, respectively) in individuals in whom the second <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> was <a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">c.217T&#x0003e;C (p.Cys73Arg)</a>, led to mild cutaneous disease [<a class="bk_pop" href="#cep.REF.desnick.2002.779">Desnick &#x00026; Astrin 2002</a>].</div></li></ul><p><b>Disease modifiers.</b> The CEP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be modulated by sequence variants in <i>ALAS2</i>, mutation of which typically causes <a href="/books/n/gene/epp-xl/">X-linked protoporphyria</a> (XLP)<i>.</i> A novel c.1757A&#x0003e;T (p.Tyr586Phe) variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 of <i>ALAS2</i> was identified in a girl with severe CEP who had <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>UROS</i> pathogenic variants [<a class="bk_pop" href="#cep.REF.tofigueras.2011.1443">To-Figueras et al 2011</a>].</p></div><div id="cep.Penetrance"><h3>Penetrance</h3><p>Most <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>UROS</i> pathogenic variants are 100% penetrant. One report to the contrary concerns a Palestinian girl who was asymptomatic (without cutaneous or hematologic signs) despite having a profound deficiency in URO-synthase activity due to homozygosity for the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant c.139T&#x0003e;C. Four of her sibs, who were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, had moderate to severe cutaneous disease [<a class="bk_pop" href="#cep.REF.ged.2004.589">Ged et al 2004</a>]. The molecular basis for the apparent non-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in one sib is unknown but possibly involves unknown modifier genes that prevent the phototoxic effects of porphyrin accumulation.</p></div><div id="cep.Nomenclature"><h3>Nomenclature</h3><p>Obsolete terms for CEP are: erythropoietic porphyria, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> porphyria, congenital hematoporphyria, and erythropoietic uroporphyria (G&#x000fc;nther's disease).</p></div><div id="cep.Prevalence"><h3>Prevalence</h3><p>CEP is a rare porphyria. To date, more than 200 cases have been reported.</p><p>CEP is pan ethnic and occurs equally in men and women [<a class="bk_pop" href="#cep.REF.katugampola.2012b.901">Katugampola et al 2012b</a>].</p></div></div><div id="cep.Genetically_Related_Allelic_Disorder"><h2 id="_cep_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p><b><i>UROS</i>.</b> No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>UROS</i>.</p><p><b><i>GATA1.</i></b> Pathogenic variants in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> are also observed in:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/gata1/"><i>GATA1</i>-related cytopenias</a>;</div></li><li class="half_rhythm"><div><a href="/books/n/gene/diamond-b/">Diamond-Blackfan anemia</a>.</div></li></ul></div><div id="cep.Differential_Diagnosis"><h2 id="_cep_Differential_Diagnosis_">Differential Diagnosis</h2><p>Other disorders presenting with a <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria (CEP)-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> are listed in <a class="figpopup" href="/books/NBK154652/table/cep.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object" rid-figpopup="figcepTdisorderstoconsiderinthediffe" rid-ob="figobcepTdisorderstoconsiderinthediffe">Table 3</a>.</p><div id="cep.T.disorders_to_consider_in_the_diffe" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Congenital Erythropoietic Porphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.disorders_to_consider_in_the_diffe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" style="text-align:left;vertical-align:middle;">Disease Name</th><th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" colspan="2" scope="colgroup" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features</th></tr><tr><th headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping</th><th headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing</th></tr></thead><tbody><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Porphyria cutanea tarda (PCT) type I (OMIM <a href="http://omim.org/entry/176090" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">176090</a>)</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:middle;">See footnote 1</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Cutaneous photosensitivity w/blistering &#x00026; friability of skin in sun-exposed areas</div></li><li class="half_rhythm"><div>Facial hypertrichosis</div></li><li class="half_rhythm"><div>Discolored urine</div></li></ul>
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Usually manifests in adulthood</div></li><li class="half_rhythm"><div>Distinct biochemical porphyrin profile</div></li></ul>
</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/porphyria-ct/">Porphyria cutanea tarda (PCT) type II</a></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"><i>UROD</i></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hep/">Hepato-erythropoietic porphyria</a></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"><i>UROD</i></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Phenotype similar to PCT</div></li><li class="half_rhythm"><div>Manifests in early childhood</div></li><li class="half_rhythm"><div>Discolored urine</div></li><li class="half_rhythm"><div>Photosensitivity</div></li></ul>
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Distinct biochemical porphyrin profile</div></li><li class="half_rhythm"><div>Developmental delay (in some)</div></li></ul>
</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hcp/">Hereditary coproporphyria</a></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"><i>CPOX</i></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">20% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals experience photosensitivity w/skin blistering in sun-exposed areas</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Acute (hepatic) porphyria</div></li><li class="half_rhythm"><div>Acute attacks of abdominal or generalized pain; can be associated w/neurologic symptoms</div></li><li class="half_rhythm"><div>Incompletely penetrant in absence of environmental inducers</div></li><li class="half_rhythm"><div>Usually manifests after puberty</div></li></ul>
</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/porphyria-var/">Variegate porphyria</a></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"><i>PPOX</i></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myeloid malignancy</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elderly adults w/myelodysplastic syndrome may exhibit features of CEP&#x000a0;<sup>2,&#x000a0;3</sup></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ebs/">Epidermolysis bullosa simplex (EBS)</a></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"><i>KRT5</i><br /><i>KRT14</i></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD&#x000a0;<sup>4</sup></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fragility of skin resulting in nonscarring blisters caused by little/no trauma</div></li><li class="half_rhythm"><div>Major &#x00026; minor subtypes share common feature of blistering above dermal-epidermal junction at the ultrastructural level</div></li></ul>
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ebj/">Junctional epidermolysis bullosa (JEB)</a></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"><i>LAMA3</i><br /><i>LAMB3</i><br /><i>LAMC2</i><br /><i>COL17A1</i></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fragility of skin &#x00026; mucous membranes, manifest by blistering w/little or no trauma</div></li><li class="half_rhythm"><div>Herlitz JEB (classic severe form): blisters present at birth or become apparent in neonatal period</div></li><li class="half_rhythm"><div>Non-Herlitz JEB: may be mild w/blistering localized to hands, feet, knees, elbows</div></li></ul>
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ebd/">Dystrophic epidermolysis bullosa</a></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" colspan="2" style="text-align:left;vertical-align:middle;"><i>COL7A1</i></td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Blisters affecting whole body may be present in neonatal period</div></li><li class="half_rhythm"><div>Oral involvement</div></li><li class="half_rhythm"><div>Corneal erosions</div></li></ul>
</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Esophageal erosions</div></li><li class="half_rhythm"><div>Severe nutritional deficiency &#x00026; secondary problems</div></li><li class="half_rhythm"><div>"Mitten" hands &#x00026; feet</div></li><li class="half_rhythm"><div>&#x0003e;90% lifetime risk of aggressive squamous cell carcinoma</div></li></ul>
</td></tr><tr><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blistering, often mild &#x00026; limited to hands, feet, knees, elbows; heals w/scarring</td><td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystrophic nails possibly the only manifestation</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="cep.TF.3.1"><p class="no_margin">80% of cases are <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> or acquired (type I PCT). Type I (or sporadic) PCT is characterized by normal URO-decarboxylase activity systemically when <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are asymptomatic. Inhibition of the enzyme activity resulting in PCT can be caused by excessive alcohol intake, hemochromatosis, viral hepatitis (mostly hepatitis C), HIV infection, certain medications, and environmental exposures such as aromatic polyhalogenated hepatotoxins. Treatment consists of eliminating or treating the underlying cause and, if symptoms persist, frequent phlebotomies or therapy with oral low-dose hydroxychloroquine.</p></div></dd><dt>2. </dt><dd><div id="cep.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#cep.REF.fritsch.1997.594">Fritsch et al [1997]</a>, <a class="bk_pop" href="#cep.REF.kontos.2003.160">Kontos et al [2003]</a>, <a class="bk_pop" href="#cep.REF.sarkany.2011.1172">Sarkany et al [2011]</a></p></div></dd><dt>3. </dt><dd><div id="cep.TF.3.3"><p class="no_margin">Affected individuals had normal erythrocyte URO-synthase activities. Presumably, the CEP-like manifestations resulted from genetic or functional changes associated with the bone marrow disorder.</p></div></dd><dt>4. </dt><dd><div id="cep.TF.3.4"><p class="no_margin">EBS caused by pathogenic variants in <i>KRT5</i> or <i>KRT14</i> is usually inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; in rare families, especially those with <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>, it can be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div></dd></dl></div></div></div></div><div id="cep.Management"><h2 id="_cep_Management_">Management</h2><div id="cep.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria (CEP), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Hematologic indices including reticulocytes and bilirubin (to assess hemolysis) and iron profile (to assess iron storage)</div></li><li class="half_rhythm"><div>Serum calcium and vitamin D concentrations; bone densitometry</div></li><li class="half_rhythm"><div>Hepatic function tests</div></li><li class="half_rhythm"><div>Dermatologic evaluation</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation</div></li><li class="half_rhythm"><div>Dental assessment</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul><p>Urine and erythrocyte porphyrins can be determined periodically after bone marrow transplant as a monitor of engraftment.</p></div><div id="cep.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Cutaneous photosensitivity.</b> There is no FDA-approved treatment for this disease or specific treatment for the photosensitivity.</p><p>Currently the only effective treatment is prevention of blistering by avoidance of light exposure, including the long-wave ultraviolet sunlight that passes through window glass or light emitted by fluorescent sources:</p><ul><li class="half_rhythm"><div>Sun protection using protective clothing including long sleeves, gloves, and wide-brimmed hats</div></li><li class="half_rhythm"><div>Protective window films for cars and windows at home as well as at school/work to prevent exposure to UV light</div></li><li class="half_rhythm"><div>Replacement of fluorescent lights with reddish incandescent bulbs or installation of filtering screens</div></li><li class="half_rhythm"><div>Reflectant sunscreens containing zinc oxide or titanium dioxide. Note, however, that these may be cosmetically unacceptable and, in any case, do not replace strict avoidance of sun/light exposure.</div></li></ul><p>Skin trauma should be avoided.</p><p>Wound care is essential to prevent infection of opened blisters. Antiseptic and topical/oral antibiotic treatment may be indicated to avoid progression to osteomyelitis and bone resorption with subsequent mutilation.</p><p>Surgical intervention may be indicated for severe mutilation (repair of microstomia, correction of ectropion, reconstruction of the nose).</p><p>Laser hair removal can be used to treat facial hypertrichosis.</p><p>Note: (1) Beta-carotene has been tried in some individuals but without significant benefit. (2) Phototherapy with narrowband ultraviolet B radiation did not show any benefit.</p><p><b>Ocular manifestations</b></p><ul><li class="half_rhythm"><div>Avoidance of damage to the eyelids and cornea by wraparound sunglasses</div></li><li class="half_rhythm"><div>Topical antibiotics for corneal ulcers, scleritis, and blepharitis</div></li><li class="half_rhythm"><div>Artificial tears and lubricants to help prevent dry eyes in those with ectropion</div></li><li class="half_rhythm"><div>Corrective surgery of eyelids to help protect the cornea from injury in those with ectropion [<a class="bk_pop" href="#cep.REF.katugampola.2012a.888">Katugampola et al 2012a</a>]</div></li></ul><p><b>Bone manifestations.</b> Bisphosphonates can be considered in individuals with osteoporosis [<a class="bk_pop" href="#cep.REF.katugampola.2012a.888">Katugampola et al 2012a</a>].</p><p><b>Hemolytic anemia</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Consider blood transfusions when hemolysis is significant.</div></li><li class="half_rhythm"><div class="half_rhythm">Chronic transfusions (every 2-4 weeks) with a target hematocrit greater than 35% can suppress erythropoiesis and decrease porphyrin production, which reduces porphyrin levels and photosensitivity [<a class="bk_pop" href="#cep.REF.piomelli.1986.1029">Piomelli et al 1986</a>].</div><div class="half_rhythm">Note: In those who receive frequent transfusions, the body iron burden can be reduced with parenteral or oral chelators [<a class="bk_pop" href="#cep.REF.pohfitzpatrick.1988">Poh-Fitzpatrick et al 1988</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Iron deficiency induced by treatment with deferasirox improved photosensitivity and hemolysis in one patient [<a class="bk_pop" href="#cep.REF.egan.2015.257">Egan at al 2015</a>].</div></li></ul><p>Note: Although oral charcoal and cholestyramine were thought to increase fecal loss of porphyrins, a clear clinical benefit has not been shown [<a class="bk_pop" href="#cep.REF.tishler.1990.645">Tishler &#x00026; Winston 1990</a>].</p><p><b>Bone marrow transplantation (BMT)</b> is the only cure for CEP and should be considered in children with severe cutaneous and hematologic involvement. Autologous as well as allogeneic stem cell transplants have been performed successfully [<a class="bk_pop" href="#cep.REF.thomas.1996.453">Thomas et al 1996</a>, <a class="bk_pop" href="#cep.REF.tezcan.1998.4053">Tezcan et al 1998</a>, <a class="bk_pop" href="#cep.REF.harada.2001.279">Harada et al 2001</a>, <a class="bk_pop" href="#cep.REF.shaw.2001.101">Shaw et al 2001</a>, <a class="bk_pop" href="#cep.REF.dupuisgirod.2005.104">Dupuis-Girod et al 2005</a>, <a class="bk_pop" href="#cep.REF.taibjee.2007.567">Taibjee et al 2007</a>, <a class="bk_pop" href="#cep.REF.faraci.2008.117">Faraci et al 2008</a>]. The age of children with CEP receiving BMT ranges from younger than one year to 13 years [<a class="bk_pop" href="#cep.REF.katugampola.2012b.901">Katugampola et al 2012b</a>]. Of note, although some of the first individuals with CEP to successfully undergo BMT in childhood should be in their 20s now [<a class="bk_pop" href="#cep.REF.thomas.1996.453">Thomas et al 1996</a>, <a class="bk_pop" href="#cep.REF.zixkieffer.1996.217">Zix-Kieffer et al 1996</a>], no follow-up information is available and the long-term outcome in individuals with CEP post-BMT is unknown.</p></div><div id="cep.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Strict avoidance of sunlight and protection from light are indicated.</p></div><div id="cep.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Vitamin D supplementation is advised as <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are predisposed to vitamin D insufficiency due to sun avoidance.</p><p>Immunization for hepatitis A and B is recommended.</p></div><div id="cep.Surveillance"><h3>Surveillance</h3><p>Monitor the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Hematologic indices including iron profile, reticulocyte count, and bilirubin to assess hemolysis every six months</div><div class="half_rhythm">Note: Individuals receiving transfusion therapy need closer monitoring.</div></li><li class="half_rhythm"><div class="half_rhythm">Iron profile on a regular basis to assess for iron overload for those who are transfusion dependent</div></li><li class="half_rhythm"><div class="half_rhythm">Hepatic function every six to twelve months</div></li><li class="half_rhythm"><div class="half_rhythm">Vitamin D 25-OH levels in all patients whether or not they are receiving vitamin D supplements</div></li></ul></div><div id="cep.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Avoidance of sunlight and UV light</div></li><li class="half_rhythm"><div>In patients with hepatic dysfunction, avoidance of drugs that may induce cholestasis (e.g., estrogens)</div></li><li class="half_rhythm"><div>In patients undergoing surgeries, use of protective filters for artificial lights in the operating room to prevent phototoxic damage [<a class="bk_pop" href="#cep.REF.wahlin.2008.1340">Wahlin et al 2008</a>]</div></li></ul></div><div id="cep.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate at-risk sibs as newborns or infants in order to identify as early as possible those who would benefit from early intervention (no phototherapy, strict sun protection) and future monitoring for signs of hemolytic anemia. Evaluations include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known;</div></li><li class="half_rhythm"><div>Biochemical testing for urinary or erythrocyte uroporphyrin I and coproporphyrin I isomer elevation if the pathogenic variants in the family are not known.</div></li></ul><p>See <a href="#cep.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="cep.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Successful pregnancies in women with CEP resulting in healthy and unaffected children have been described [<a class="bk_pop" href="#cep.REF.hallai.2007.622">Hallai et al 2007</a>, <a class="bk_pop" href="#cep.REF.katugampola.2012b.901">Katugampola et al 2012b</a>].</p><p>Protective filters for artificial lights should be used in the delivery/operating room to prevent phototoxic damage to the mother during delivery [<a class="bk_pop" href="#cep.REF.wahlin.2008.1340">Wahlin et al 2008</a>].</p></div><div id="cep.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>To date, <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> has been evaluated only in the murine CEP model [<a class="bk_pop" href="#cep.REF.de_verneuil.2008.615">de Verneuil et al 2008</a>, <a class="bk_pop" href="#cep.REF.fortian.2011.13127">Fortian et al 2011</a>, <a class="bk_pop" href="#cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="cep.Genetic_Counseling"><h2 id="_cep_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="cep.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Congenital erythropoietic porphyria (CEP) caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>UROS</i> pathogenic variants is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p>CEP caused by a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. Note: To date only three such individuals have been identified [<a class="bk_pop" href="#cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bk_pop" href="#cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</p></div><div id="cep.Risk_to_Family_Members__Autosomal_Re"><h3>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>UROS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Unless an individual with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, his/her offspring will be obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>UROS</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>UROS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="cep.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>UROS</i> pathogenic variants in the family.</p></div><div id="cep.Risk_to_Family_Members__XLinked_Inhe"><h3>Risk to Family Members &#x02013; X-Linked Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disease nor will he be a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of the <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>Women who have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> son and another affected male relative are obligate heterozygotes.</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a carrier. The frequency of <i>de novo</i>
<i>GATA1</i> pathogenic variants is unknown.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs of a male proband depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be heterozygotes and can be either asymptomatic or have a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with predominantly hematologic abnormalities due to skewed X-inactivation [<a class="bk_pop" href="#cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bk_pop" href="#cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males transmit the <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</p><ul><li class="half_rhythm"><div>All of their daughters, who will be (heterozygotes) carriers and can be either asymptomatic or have a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with predominantly hematologic abnormalities due to skewed X-inactivation [<a class="bk_pop" href="#cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bk_pop" href="#cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>];</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul><p><b>Other family members.</b> The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being carriers and the aunts' offspring, depending on their gender, may be at risk of being carriers or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</p></div><div id="cep.Carrier_Heterozygote_Detection_1"><h3>Carrier (Heterozygote) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p></div><div id="cep.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#cep.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="cep.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>UROS</i> or <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for CEP are possible.</p><p><b>Biochemical genetic testing.</b> Prenatal diagnosis is also possible by demonstrating markedly deficient URO-synthase activity in cultured amniotic cells or chorionic villi cells, and/or markedly elevated uroporphyrin I and coproporphyrin I concentrations in amniotic fluid (see <a class="figpopup" href="/books/NBK154652/table/cep.T.biochemical_characteristics_of_con/?report=objectonly" target="object" rid-figpopup="figcepTbiochemicalcharacteristicsofcon" rid-ob="figobcepTbiochemicalcharacteristicsofcon">Table 1</a>).</p><p>Note: It is assumed that an elevation of uroporphyrin I and coproporphyrin I concentrations in amniotic fluid is also present in <i>GATA1</i>-related CEP; however, at this time data are insufficient to confirm this hypothesis.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="cep.Resources"><h2 id="_cep_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>British &#x00026; Irish Porphyria Network (BIPNET)</b></div><div>United Kingdom</div><div><a href="http://www.bipnet.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.bipnet.org.uk</a></div></li><li class="half_rhythm"><div><b>British Porphyria Association</b></div><div>United Kingdom</div><div><b>Phone:</b> 0300 30 200 30</div><div><b>Email:</b> helpline@porphyria.org.uk</div><div><a href="http://www.porphyria.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyria.org.uk</a></div></li><li class="half_rhythm"><div><b>Canadian Association for Porphyria/Association Canadienne de Porphyrie</b></div><div>Canada</div><div><a href="http://canadianassociationforporphyria.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.canadianassociationforporphyria.ca</a></div></li><li class="half_rhythm"><div><b>Find a Porphyria Expert</b></div><div>American Porphyria Foundation</div><div><a href="https://www.porphyriafoundation.org/for-patients/porphyria-experts/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org/for-patients/porphyria-experts</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=congenitalerythropoieticporphyria" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Congenital erythropoietic porphyria</a></div></li><li class="half_rhythm"><div><b>Porphyria South Africa</b></div><div>South Africa</div><div><b>Phone:</b> +27 21-4066332</div><div><b>Fax:</b> +27 21-4066061</div><div><b>Email:</b> Peter.Meissner@uct.ac.za</div><div><a href="http://www.porphyria-patients.uct.ac.za/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria for Patients</a></div></li><li class="half_rhythm"><div><b>American Porphyria Foundation (APF)</b></div><div>915 St. Elmo Avenue</div><div>Suite 200</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 866-APF-3635 (toll-free); 301-347-7166</div><div><b>Email:</b> porphyrus@porphyriafoundation.com</div><div><a href="https://www.porphyriafoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org</a></div></li><li class="half_rhythm"><div><b>European Porphyria Network</b></div><div><b>Email:</b> contact@porphyria.eu</div><div><a href="http://porphyria.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyria.eu</a></div></li><li class="half_rhythm"><div><b>Swedish Porphyria Patients' Association</b></div><div>Karolinska Universitetssjukhuset</div><div>Huddinge M 96</div><div>Stockholm Stockholms Lan SE-141 86</div><div>Sweden</div><div><b>Phone:</b> +46 8 711 56 09 </div><div><b>Email:</b> porfyrisjukdomar@gmail.com</div><div><a href="http://www.porfyri.se" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porfyri.se</a></div></li></ul></div><div id="cep.Molecular_Genetics"><h2 id="_cep_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="cep.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Congenital Erythropoietic Porphyria: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_cep.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_cep.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_cep.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_cep.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_cep.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_cep.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_cep.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2623" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>GATA1</i></a></td><td headers="hd_b_cep.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2623" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xp11<wbr style="display:inline-block"></wbr>​.23</a></td><td headers="hd_b_cep.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P15976" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Erythroid transcription factor</a></td><td headers="hd_b_cep.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/GATA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GATA1 @ LOVD</a></td><td headers="hd_b_cep.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GATA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GATA1</a></td><td headers="hd_b_cep.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=GATA1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">GATA1</a></td></tr><tr><td headers="hd_b_cep.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7390" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>UROS</i></a></td><td headers="hd_b_cep.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7390" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">10q26<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_cep.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P10746" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Uroporphyrinogen-III synthase</a></td><td headers="hd_b_cep.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/UROS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UROS database</a></td><td headers="hd_b_cep.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=UROS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UROS</a></td><td headers="hd_b_cep.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=UROS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UROS</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="cep.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="cep.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Congenital Erythropoietic Porphyria (<a href="/omim/263700,305371,606938" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/263700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">263700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/305371" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">305371</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GATA-BINDING PROTEIN 1; GATA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606938" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606938</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UROPORPHYRINOGEN III SYNTHASE; UROS</td></tr></tbody></table></div></div><p><b><i>UROS</i></b></p><p><b>Gene structure.</b>
<i>UROS</i> (<a href="/nuccore/NM_000375.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000375.2</a>) has ten exons and two <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> transcripts, generated by alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> directed from unique housekeeping and erythroid-specific promoters. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK154652/#cep.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Approximately 50 <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants (see <a href="/books/NBK154652/#cep.molgen.TA">Table A</a>, <b>HGMD</b>) have been identified in <i>UROS</i>, many of which result in an unstable or functionally severely impaired enzyme. Pathogenic loss-of-function variants include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants and small deletions and insertions (<a class="figpopup" href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figcepTurospathogenicvariantsdiscussed" rid-ob="figobcepTurospathogenicvariantsdiscussed">Table 4</a>). Regulatory pathogenic variants are located in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 1 upstream of the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 ATG.</p><div id="cep.T.uros_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>UROS</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK154652/table/cep.T.uros_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__cep.T.uros_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.139T&#x0003e;C</td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser47Pro</td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000375.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000375<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_000366.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000366<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.197C&#x0003e;T</td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala66Val</td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.217T&#x0003e;C</td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys73Arg</td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.244G&#x0003e;T</td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val82Phe</td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.311C&#x0003e;T</td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala104Val</td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.673G&#x0003e;A</td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly225Ser</td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1 hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2 hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_3" colspan="3" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic variants in the erythroid-specific <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a></b></td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-203T&#x0003e;C<br />(-70T&#x0003e;C)&#x000a0;<sup>2</sup></td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000375.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000375<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-209G&#x0003e;A<br />(-76G&#x0003e;A)</td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-219C&#x0003e;A<br />(-86C&#x0003e;A)</td></tr><tr><td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-223C&#x0003e;A<br />(-90C&#x0003e;A)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">NA = not applicable.</p></div></dd><dt>1. </dt><dd><div id="cep.TF.4.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="cep.TF.4.2"><p class="no_margin">Traditional nomenclature [<a class="bk_pop" href="#cep.REF.solis.2001.753">Solis et al 2001</a>, <a class="bk_pop" href="#cep.REF.desnick.2002.779">Desnick &#x00026; Astrin 2002</a>]</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal gene encodes the enzyme uroporphyrinogen III synthase, which consists of 265 amino acids (<a href="/protein/NP_000366.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000366.1</a>).</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>UROS</i> pathogenic variants result in either a nonfunctional or a partially functional enzyme.</p><p><b><i>GATA1</i></b></p><p><b>Gene structure.</b>
<i>GATA1</i> (<a href="/nuccore/NM_002049.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002049.3</a>) has five coding exons and two alternative untranslated regions (UTRs) (one 3' and one 5'). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK154652/#cep.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> A <i>GATA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (p.Arg216Trp) has been identified in three unrelated individuals with CEP and hematologic abnormalities (thrombocytopenia, dyserythropoietic anemia, beta-thalassemia) [<a class="bk_pop" href="#cep.REF.phillips.2007.2618">Phillips et al 2007</a>, <a class="bk_pop" href="#cep.REF.di_pierro.2015.491">Di Pierro et al 2015</a>].</p><p>See <a href="/books/n/gene/gata1/#gata1.Molecular_Genetics"><i>GATA1</i>-Related X-Linked Cytopenia, Molecular Genetics</a>, <b>Pathogenic variants</b>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> GATA1 (<a href="/protein/NP_002040.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002040.1</a>) is a <a class="def" href="/books/n/gene/glossary/def-item/transcription-factor/">transcription factor</a> that normally regulates the expression of URO-synthase in developing erythrocytes.</p><p>See <a href="/books/n/gene/gata1/#gata1.Molecular_Genetics"><i>GATA1</i>-Related X-Linked Cytopenia, Molecular Genetics</a>, <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The p.Arg216Trp <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is predicted to dramatically alter the binding of GATA1 to URO-synthase, resulting in significantly reduced (~20% of normal) URO-synthase activity [<a class="bk_pop" href="#cep.REF.phillips.2007.2618">Phillips et al 2007</a>].</p><p>See <a href="/books/n/gene/gata1/#gata1.Molecular_Genetics"><i>GATA1</i>-Related X-Linked Cytopenia, Molecular Genetics</a>, <b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>.</p></div><div id="cep.References"><h2 id="_cep_References_">References</h2><div id="cep.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="cep.REF.anderson.2001">Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: Scriver CR, Beaudet AL, Sly WS, eds. <em>The Metabolic and Molecular Basis of Inherited Disease.</em> 8 ed. New York, NY: McGraw-Hill; 2001:2991.</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.bickers.1987.261">Bickers DR. The dermatologic manifestations of human porphyria. <span><span class="ref-journal">Ann N Y Acad Sci. </span>1987;<span class="ref-vol">514</span>:261–7.</span> [<a href="/pubmed/3327430" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3327430</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.bishop.2006.645">Bishop DF, Johansson A, Phelps R, Shady AA, Ramirez MC, Yasuda M, Caro A, Desnick RJ. Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions. <span><span class="ref-journal">Am J Hum Genet. </span>2006;<span class="ref-vol">78</span>:645–58.</span> [<a href="/pmc/articles/PMC1424695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1424695</span></a>] [<a href="/pubmed/16532394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16532394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.boulechfar.1992.320">Boulechfar S, Da Silva V, Deybach JC, Nordmann Y, Grandchamp B, de Verneuil H. Heterogeneity of mutations in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. <span><span class="ref-journal">Hum Genet. </span>1992;<span class="ref-vol">88</span>:320–4.</span> [<a href="/pubmed/1733834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1733834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.da_khadahmane.2001.180">Da&#x000ef;kha-Dahmane F, Dommergues M, Narcy F, Gubler MC, Dumez Y, Gauthier E, Nordmann Y, Nessmann C, Terrasse G, Muller F. Congenital erythropoietic porphyria: prenatal diagnosis and autopsy findings in two sibling fetuses. <span><span class="ref-journal">Pediatr Dev Pathol. </span>2001;<span class="ref-vol">4</span>:180–4.</span> [<a href="/pubmed/11178635" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11178635</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.dawe.2002.680">Dawe SA, Peters TJ, Du Vivier A, Creamer JD. Congenital erythropoietic porphyria: dilemmas in present day management. <span><span class="ref-journal">Clin Exp Dermatol. </span>2002;<span class="ref-vol">27</span>:680–3.</span> [<a href="/pubmed/12472546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12472546</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.de_verneuil.2008.615">de Verneuil H, Robert-Richard E, Ged C, Mazurier F, Richard E, Moreau-Gaudry F. Successful gene therapy of mice with congenital erythropoietic porphyria. <span><span class="ref-journal">Med Sci (Paris). </span>2008;<span class="ref-vol">24</span>:615–20.</span> [<a href="/pubmed/18601879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18601879</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.desnick.2002.779">Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">117</span>:779–95.</span> [<a href="/pubmed/12060112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12060112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.desnick.1998.77">Desnick RJ, Glass IA, Xu W, Solis C, Astrin KH. Molecular genetics of congenital erythropoietic porphyria. <span><span class="ref-journal">Semin Liver Dis. </span>1998;<span class="ref-vol">18</span>:77–84.</span> [<a href="/pubmed/9516681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9516681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.di_pierro.2015.491">Di Pierro E, Russo R, Karakas Z, Brancaleoni V, Gambale A, Kurt I, Winter SS, Granata F, Czuchlewski DR, Langella C, Iolascon A, Cappellini MD. Congenital erythropoietic porphyria linked to GATA1-R216W mutation: challenges for diagnosis. <span><span class="ref-journal">Eur J Haematol. </span>2015;<span class="ref-vol">94</span>:491–7.</span> [<a href="/pubmed/25251786" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25251786</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.dupuisgirod.2005.104">Dupuis-Girod S, Akkari V, Ged C, Galambrun C, Keba&#x000ef;li K, Deybach JC, Claudy A, Geburher L, Philippe N, de Verneuil H, Bertrand Y. Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (G&#x000fc;nther disease). <span><span class="ref-journal">Eur J Pediatr. </span>2005;<span class="ref-vol">164</span>:104–7.</span> [<a href="/pubmed/15703981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15703981</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.egan.2015.257">Egan DN, Yang Z, Phillips J, Abkowitz JL. Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria. <span><span class="ref-journal">Blood. </span>2015;<span class="ref-vol">126</span>:257–61.</span> [<a href="/pmc/articles/PMC4497965/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4497965</span></a>] [<a href="/pubmed/25972160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25972160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.faraci.2008.117">Faraci M, Morreale G, Boeri E, Lanino E, Dallorso S, Dini G, Scuderi F, Cohen A, Cappelli B. Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. <span><span class="ref-journal">Pediatr Transplant. </span>2008;<span class="ref-vol">12</span>:117–20.</span> [<a href="/pubmed/18186900" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18186900</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.fortian.2011.13127">Fortian A, Gonz&#x000e1;lez E, Casta&#x000f1;o D, Falcon-Perez JM, Millet O. Intracellular rescue of the uroporphyrinogen III synthase activity in enzymes carrying the hotspot mutation C73R. <span><span class="ref-journal">J Biol Chem. </span>2011;<span class="ref-vol">286</span>:13127–33.</span> [<a href="/pmc/articles/PMC3075659/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3075659</span></a>] [<a href="/pubmed/21343304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21343304</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.frank.1998.225">Frank J, Wang X, Lam HM, Aita VM, Jugert FK, Goerz G, Merk HF, Poh-Fitzpatrick MB, Christiano AM. C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. <span><span class="ref-journal">Ann Hum Genet. </span>1998;<span class="ref-vol">62</span>:225–30.</span> [<a href="/pubmed/9803266" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9803266</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.fritsch.1997.594">Fritsch C, Bolsen K, Ruzicka T, Goerz G. Congenital erythropoietic porphyria. <span><span class="ref-journal">J Am Acad Dermatol. </span>1997;<span class="ref-vol">36</span>:594–610.</span> [<a href="/pubmed/9092747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9092747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.ged.2004.589">Ged C, M&#x000e9;garban&#x000e9; H, Chouery E, Lalanne M, M&#x000e9;garban&#x000e9; A, de Verneuil H. Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling. <span><span class="ref-journal">J Invest Dermatol. </span>2004;<span class="ref-vol">123</span>:589–91.</span> [<a href="/pubmed/15304101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15304101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.hallai.2007.622">Hallai N, Anstey A, Mendelsohn S, Williams J, Evans-Jones G, Malick S, Badminton MN. Pregnancy in a patient with congenital erythropoietic porphyria. <span><span class="ref-journal">N Engl J Med. </span>2007;<span class="ref-vol">357</span>:622–3.</span> [<a href="/pubmed/17687144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17687144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.harada.2001.279">Harada FA, Shwayder TA, Desnick RJ, Lim HW. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. <span><span class="ref-journal">J Am Acad Dermatol. </span>2001;<span class="ref-vol">45</span>:279–82.</span> [<a href="/pubmed/11464191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11464191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.katugampola.2012a.888">Katugampola RP, Anstey AV, Finlay AY, Whatley S, Woolf J, Mason N, Deybach JC, Puy H, Ged C, de Verneuil H, Hanneken S, Minder E, Schneider-Yin X, Badminton MN. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. <span><span class="ref-journal">Br J Dermatol. </span>2012a;<span class="ref-vol">167</span>:888–900.</span> [<a href="/pubmed/22804244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22804244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.katugampola.2012b.901">Katugampola RP, Badminton MN, Finlay AY, Whatley S, Woolf J, Mason N, Deybach JC, Puy H, Ged C, de Verneuil H, Hanneken S, Minder E, Schneider-Yin X, Anstey AV. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. <span><span class="ref-journal">Br J Dermatol. </span>2012b;<span class="ref-vol">167</span>:901–13.</span> [<a href="/pubmed/22816431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22816431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.kaufman.1967.210">Kaufman BM, Vickers HR, Rayne J, Ryan TJ. Congenital erythropoietic porphyria. Report of a case. <span><span class="ref-journal">Br J Dermatol. </span>1967;<span class="ref-vol">79</span>:210–20.</span> [<a href="/pubmed/6024737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6024737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.kontos.2003.160">Kontos AP, Ozog D, Bichakjian C, Lim HW. Congenital erythropoietic porphyria associated with myelodysplasia presenting in a 72-year-old man: report of a case and review of the literature. <span><span class="ref-journal">Br J Dermatol. </span>2003;<span class="ref-vol">148</span>:160–4.</span> [<a href="/pubmed/12534613" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12534613</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.laorr.1994.307">Laorr A, Greenspan A. Severe osteopenia in congenital erythropoietic porphyria. <span><span class="ref-journal">Can Assoc Radiol J. </span>1994;<span class="ref-vol">45</span>:307–9.</span> [<a href="/pubmed/8062123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8062123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.oguz.1993.671">Oguz F, Sidal M, Bayram C, Sansoy N, Hekim N. Ocular involvement in two symptomatic congenital erythropoietic porphyria. <span><span class="ref-journal">Eur J Pediatr. </span>1993;<span class="ref-vol">152</span>:671–3.</span> [<a href="/pubmed/8404971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8404971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.pain.1975.621">Pain RW, Welch FW, Woodroffe AJ, Handley DA, Lockwood WH. Erythropoietic uroporphyria of Gunther first presenting at 58 years with positive family studies. <span><span class="ref-journal">Br Med J. </span>1975;<span class="ref-vol">3</span>:621–3.</span> [<a href="/pmc/articles/PMC1674443/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1674443</span></a>] [<a href="/pubmed/1164638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1164638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.phillips.2007.2618">Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:2618–21.</span> [<a href="/pmc/articles/PMC1852202/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1852202</span></a>] [<a href="/pubmed/17148589" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17148589</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.piomelli.1986.1029">Piomelli S, Poh-Fitzpatrick MB, Seaman C, Skolnick LM, Berdon WE. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. <span><span class="ref-journal">N Engl J Med. </span>1986;<span class="ref-vol">314</span>:1029–31.</span> [<a href="/pubmed/3960070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3960070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.pohfitzpatrick.1988">Poh-Fitzpatrick MB, Piomelli S, Seaman C, Skolnick LM. Congenital erythropoietic porphyria: complete suppression of symptoms by long-term high-level transfusion with deferoxamine infusion iron rescue. In: Orfanos CE, Stadler R, Gollnick H, eds. <em>Dermatology in Five Continents</em>. Berlin, Germany: Springer Verlag; 1988:876-9.</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.pohfitzpatrick.1985">Poh-Fitzpatrick MB. Porphyrin sensitized cutaneous photosensitivity - pathogenesis and treatment. In: Disler PB, Moore MR, eds. <em>Porphyria-Clinics in Dermatology</em>. Philadelphia, PA: Lippincott; 1985:41-82. [<a href="/pubmed/3916834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3916834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.pohfitzpatrick.1986.291">Poh-Fitzpatrick MB. The erythropoietic porphyrias. <span><span class="ref-journal">Dermatol Clin. </span>1986;<span class="ref-vol">4</span>:291–6.</span> [<a href="/pubmed/3955899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3955899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.sarkany.2011.1172">Sarkany RP, Ibbotson SH, Whatley SD, Lawrence CM, Gover P, Mufti GJ, Murphy GM, Masters GS, Badminton MN, Elder GH. Erythropoietic uroporphyria associated with myeloid malignancy is likely distinct from autosomal recessive congenital erythropoietic porphyria. <span><span class="ref-journal">J Invest Dermatol. </span>2011;<span class="ref-vol">131</span>:1172–5.</span> [<a href="/pubmed/21326293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21326293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.schmid.1955.416">Schmid R, Schwartz S, Sundberg RD. Erythropoietic (congenital) porphyria: a rare abnormality of the normoblasts. <span><span class="ref-journal">Blood. </span>1955;<span class="ref-vol">10</span>:416–28.</span> [<a href="/pubmed/14363322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14363322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.shady.2002.980">Shady AA, Colby BR, Cunha LF, Astrin KH, Bishop DF, Desnick RJ. Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">117</span>:980–7.</span> [<a href="/pubmed/12060141" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12060141</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.shaw.2001.101">Shaw PH, Mancini AJ, McConnell JP, Brown D, Kletzel M. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. <span><span class="ref-journal">Bone Marrow Transplant. </span>2001;<span class="ref-vol">27</span>:101–5.</span> [<a href="/pubmed/11244446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11244446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.siddique.2011.97">Siddique SS, Gonzalez-Gonzalez LA, Thakuria P, Chang PY, Foster CS. Scleral necrosis in a patient with congenital erythropoietic porphyria. <span><span class="ref-journal">Cornea. </span>2011;<span class="ref-vol">30</span>:97–9.</span> [<a href="/pubmed/20847674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20847674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.solis.2001.753">Solis C, Aizencang GI, Astrin KH, Bishop DF, Desnick RJ. Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. <span><span class="ref-journal">J Clin Invest. </span>2001 Mar;<span class="ref-vol">107</span>:753–62.</span> [<a href="/pmc/articles/PMC208941/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC208941</span></a>] [<a href="/pubmed/11254675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11254675</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.stenson.2003.577">Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN. Human Gene Mutation Database (HGMD): 2003 update. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">21</span>:577–81.</span> [<a href="/pubmed/12754702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12754702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.taibjee.2007.567">Taibjee SM, Stevenson OE, Abdullah A, Tan CY, Darbyshire P, Moss C, Goodyear H, Heagerty A, Whatley S, Badminton MN. Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma. <span><span class="ref-journal">Br J Dermatol. </span>2007;<span class="ref-vol">156</span>:567–71.</span> [<a href="/pubmed/17300251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17300251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.tezcan.1998.4053">Tezcan I, Xu W, Gurgey A, Tuncer M, Cetin M, Oner C, Yetgin S, Ersoy F, Aizencang G, Astrin KH, Desnick RJ. Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. <span><span class="ref-journal">Blood. </span>1998;<span class="ref-vol">92</span>:4053–8.</span> [<a href="/pubmed/9834209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9834209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.thomas.1996.453">Thomas C, Ged C, Nordmann Y, de Verneuil H, Pellier I, Fischer A, Blanche S. Correction of congenital erythropoietic porphyria by bone marrow transplantation. <span><span class="ref-journal">J Pediatr. </span>1996;<span class="ref-vol">129</span>:453–6.</span> [<a href="/pubmed/8804339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8804339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.tishler.1990.645">Tishler PV, Winston SH. Rapid improvement in the chemical pathology of congenital erythropoietic porphyria with treatment with superactivated charcoal. <span><span class="ref-journal">Methods Find Exp Clin Pharmacol. </span>1990;<span class="ref-vol">12</span>:645–8.</span> [<a href="/pubmed/2084460" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2084460</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.tofigueras.2011.1443">To-Figueras J, Ducamp S, Clayton J, Badenas C, Delaby C, Ged C, Lyoumi S, Gouya L, de Verneuil H, Beaumont C, Ferreira GC, Deybach JC, Herrero C, Puy H. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:1443–51.</span> [<a href="/pubmed/21653323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21653323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.venkatesh.2000.314">Venkatesh P, Garg SP, Kumaran E, Tewari HK. Congenital porphyria with necrotizing scleritis in a 9-year-old child. <span><span class="ref-journal">Clin Experiment Ophthalmol. </span>2000;<span class="ref-vol">28</span>:314–8.</span> [<a href="/pubmed/11021563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11021563</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.wahlin.2008.1340">Wahlin S, Srikanthan N, Hamre B, Harper P, Brun A. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. <span><span class="ref-journal">Liver Transpl. </span>2008;<span class="ref-vol">14</span>:1340–6.</span> [<a href="/pubmed/18756472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18756472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.warner.1992.693">Warner CA, Yoo HW, Roberts AG, Desnick RJ. Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene. <span><span class="ref-journal">J Clin Invest. </span>1992;<span class="ref-vol">89</span>:693–700.</span> [<a href="/pmc/articles/PMC442904/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC442904</span></a>] [<a href="/pubmed/1737856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1737856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.weston.1978.921">Weston MJ, Nicholson DC, Lim CK, Clark KG, Macdonald A, Henderson MA, Williams R. Congenital erythropoietic uroporphyria (G&#x000fc;nther's disease) presenting in a middle aged man. <span><span class="ref-journal">Int J Biochem. </span>1978;<span class="ref-vol">9</span>:921–6.</span> [<a href="/pubmed/744297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 744297</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="cep.REF.zixkieffer.1996.217">Zix-Kieffer I, Langer B, Eyer D, Acar G, Racadot E, Schlaeder G, Oberlin F, Lutz P. Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease). <span><span class="ref-journal">Bone Marrow Transplant. </span>1996;<span class="ref-vol">18</span>:217–20.</span> [<a href="/pubmed/8832020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8832020</span></a>]</div></li></ul></div></div><div id="cep.Chapter_Notes"><h2 id="_cep_Chapter_Notes_">Chapter Notes</h2><div id="cep.Acknowledgments"><h3>Acknowledgments</h3><p>The CEP contribution to <i>GeneReviews</i> was supported in part by the Porphyrias Consortium of the NIH-supported <a href="https://www.rarediseasesnetwork.org/cms/porphyrias" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rare Diseases Clinical Research Network</a> (NIH grant: 5 U54 DK083909), including:</p><ul><li class="half_rhythm"><div>Dr Karl Anderson, University of Texas Medical Branch, Galveston, TX</div></li><li class="half_rhythm"><div>Dr Montgomery Bissell, University of California, San Francisco, CA</div></li><li class="half_rhythm"><div>Dr Joseph Bloomer, University of Alabama, Birmingham, AL</div></li><li class="half_rhythm"><div>Dr Herbert Bonkovsky, Wake Forest University Health Sciences, Winston-Salem, NC</div></li><li class="half_rhythm"><div>Dr Robert J Desnick, Icahn School of Medicine at Mount Sinai, New York, NY</div></li><li class="half_rhythm"><div>Dr John Phillips, University of Utah School of Medicine, Salt Lake City, UT</div></li></ul></div><div id="cep.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>7 April 2016 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>12 September 2013 (me) Review posted live</div></li><li class="half_rhythm"><div>5 March 2013 (ae) Original submission</div></li></ul></div></div><div><dl class="temp-labeled-list small"><dt>*</dt><dd><div id="cep.Tb.an4"><p class="no_top_margin">See Chapter Notes, <a href="#cep.Acknowledgments">Acknowledgments</a>.</p></div></dd></dl></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK154652</span><span class="label">PMID: <a href="/pubmed/24027798" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">24027798</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cda1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cftd/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK154652&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK154652/?report=reader">PubReader</a></li><li><a href="/books/NBK154652/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK154652" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK154652" style="display:none" title="Cite this Page"><div class="bk_tt">Erwin A, Balwani M, Desnick RJ; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Congenital Erythropoietic Porphyria. 2013 Sep 12 [Updated 2016 Apr 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK154652/pdf/Bookshelf_NBK154652.pdf">PDF version of this page</a> (503K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#cep.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#cep.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#cep.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#cep.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#cep.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#cep.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#cep.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#cep.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#cep.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#cep.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#cep.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7390[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">UROS</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK154652+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3052224" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3052224" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3052224" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3052224" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23016163" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erythropoietic Protoporphyria, Autosomal Recessive</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erythropoietic Protoporphyria, Autosomal Recessive<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Balwani M, Bloomer J, Desnick R, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409301" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Protoporphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Protoporphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Balwani M, Desnick R, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30685241" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital erythropoietic porphyria: Recent advances.</a><span class="source">[Mol Genet Metab. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital erythropoietic porphyria: Recent advances.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Erwin AL, Desnick RJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Genet Metab. 2019 Nov; 128(3):288-297. Epub 2018 Dec 27.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301769" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diamond-Blackfan Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Diamond-Blackfan Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Clinton C, Gazda HT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301538" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">GATA1</i>-Related X-Linked Cytopenia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">GATA1</i>-Related X-Linked Cytopenia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chou ST, Kacena MA, Weiss MJ, Raskind WH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=24027798" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=24027798" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc901675f66d18aa706a40">Congenital Erythropoietic Porphyria - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Congenital Erythropoietic Porphyria - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:10:46-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C8AFEDFC888410000000003AE01C1&amp;ncbi_session=CE8C8AFEDFC90161_0942SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK154652%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK154652&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK154652/&amp;ncbi_pagename=Congenital Erythropoietic Porphyria - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C8AFEDFC90161_0942SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>